The brand lane against the discount claim: manufacturer-priced Zepbound access versus aggressively marketed compounded pricing with minimal documentation.
The two models
Ro plays the insurance-navigation game better than most of the category: coverage checks, prior-authorization support, and — since its 2025 arrangement to dispense Lilly’s Zepbound vials — a direct lane to brand product at manufacturer self-pay prices. Its own fees, effective monthly totals, and compounded posture remain in our verification queue, so no Ro figure appears here yet.
Remedy Meds markets aggressively on price while publishing comparatively little about its clinical workflow, pharmacy sourcing, and full fee stack — the documentation gap itself is the finding so far. It sits in our verification queue, and until that pass completes, no Remedy figure or score appears on this site.
Verified vs pending — read this before the marketing
Neither provider on this page has completed price verification, so this comparison stays structural — business models, pricing architecture, and the questions each must answer — with zero advertised numbers repeated as facts. The only verified figures on this site today sit in the ledger.
Certainty versus price theater
Ro’s strongest card is product certainty — brand vials, manufacturer pricing, the counterfeit question mooted. Remedy’s card is a number — unverified, thinly documented, and exactly the shape teaser anatomy teaches you to distrust until checkout proves it. The honest frame: one model’s risks are mostly priced in; the other’s are mostly undisclosed. Verification pending on both rows either way.
Go deeper
Full files: Ro · Remedy Meds. Decision tools: the quiz routes by coverage and priorities; the calculator turns any quote into a true 12-month number; the ledger holds every verified figure and every pending slot.